3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
5
Thoracic
2
Gastrointestinal
2
Head & Neck
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
84
Triple Negative Breast Neoplasms
24
Neoplasm Metastasis
9
Breast Neoplasms, Male
8
Carcinoma, Intraductal, Noninfiltrating
7
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Breast Carcinoma In Situ
5
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Inflammatory Breast Neoplasms
4
Endometrial Neoplasms
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Anatomic Stage IV Breast Cancer AJCC v8
3
Thyroid Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Rectal Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Interventions
pembrolizumab
9
Cyclophosphamide
6
fludarabine phosphate
4
aldesleukin
3
Radiotherapy
3
Gemcitabine
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
temsirolimus
2
sargramostim
2
motexafin gadolinium
2
liposomal doxorubicin
2
fludarabine
2
entinostat
2
durvalumab
2
belinostat
2
atezolizumab
2
Sirolimus
2
Paclitaxel
2
Methods
2
Metformin
2
Irinotecan
2
Interferon-alpha
2
Bortezomib
2
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2
valspodar
1
tremelimumab
1
tocilizumab
1
tanespimycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Biopsy
×
Breast
×
Clear all
NCT07327489
2026-01-08
ELEPHAS-05
Elephas
Recruiting
2,000 enrolled